This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Global Huntington%s Disease Therapeutics Industry

NEW YORK, Aug. 6, 2013 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Global Huntington%s Disease Therapeutics Industry

This report analyzes the worldwide markets for Huntington's Disease Therapeutics in US$ Million. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2018. Also, a six-year historic analysis is provided for these markets .The report profiles 35 companies including Alnylam Pharmaceuticals, Inc., AmpliPhi Biosciences Corp., Ceregene, Inc., Cortex Pharmaceuticals, Inc., Intellect Neurosciences Incorporation, Prana Biotechnology Limited, Raptor Pharmaceuticals Corp., Teva Pharmaceutical Industries Ltd., Trophos SA, Valeant Pharmaceuticals International, Inc., and Vertex Pharmaceuticals Incorporated.

Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONSStudy Reliability and Reporting Limitations I-1Disclaimers I-2Data Interpretation & Reporting Level I-2Quantitative Techniques & Analytics I-3Product Definitions and Scope of Study I-3

II. EXECUTIVE SUMMARY1. INDUSTRY OVERVIEW II-1Prelude II-1 Huntington's Disease - Few Quick Facts II-1Market Opportunity II-2Competition in the Global HD Therapeutics Market is Nonexistent II-3Effectiveness of Current HD Management Strategies II-3HD Treatment and Drugs II-4Alternative Treatment Approaches for Huntington's disease II-5Alternate Approaches and Therapies II-5Off-Label Prescriptions II-5Select Off-Label Drugs Prescribed for Huntington's Disease II-6

2. HD THERAPEUTICS MARKET TRENDS II-7Companies Boost R&D Spending for HD Therapeutics II-7Improved Diagnostics Fueling Interest of Companies in HD Research II-7Support Organizations Play an Instrumental Role in HD Researchand Awareness II-7Public-Private Partnerships: A Shot in the Arm II-8HD Research Attracts 'Big Pharma' Investment II-8Pre-Symptomatic Patients to Expand Market Base II-8HDSA Pushes for Improvement in Medicare Funding for Huntington's Disease II-9GINA for Reducing Discrimination Faced by People with HD II-9

3. HD RESEARCH AND DRUG PIPELINE II-11A Quick Primer II-11Drug Development Pipeline Reveals Promising Picture II-11Select Drugs and Supplements in HD Research Pipeline (2011) II-11Overview of Select Pipeline Drugs II-13Huntexil™ (Pridopidine) II-13 RP103 (DR Cysteamine) II-13PBT2 II-14Other Novel Approaches for HD Treatment II-14Cellular Delivery of Neurotropic Agents II-14Cogane II-14COPREXA II-15Histone Deacetylases (HDAC) II-15Melatonin, Coenzyme Q-Free Radical Scavengers II-15RNAi - RNA Interference II-15Small Molecule Inhibitor of Polyglutamine Interaction II-16TELOMICS™ II-16

4. RESEARCH BREAKTHROUGHS IN HD ARENA II-17Lund University Researchers Successfully Map Functionality ofHypothalamus in HD II-17MIB, University of Lisbon and University of LeicesterDemonstrate Latest Findings on KMO Enzyme II-17Latest TRACK-HD Findings Demonstrate Early Identification of Huntington's Disease Progression in Patients II-17Researchers at BUSM, MGH, Columbia University and McLean BTRCDemonstrate Impact of Huntington's Disease on Human Brain II-18Researchers Demonstrate Significance of TFEB and PGC-1alphaProteins in Prevention of HD II-18Florey Neuroscience Institutes Demonstrates Importance ofCognitive Stimulation in HD Patients II-19 University of Wisconsin-Madison Waisman Center DemonstratesStem Cell Therapy Potential for Treating HD II-19NUI Galway Announces Discovery of Experimental Drugs withPotential for Slowing Progress of HD II-19Lawrence Berkeley National Laboratory Designs Compound forSuppressing HD Symptoms II-20Development of HD Affected Human Brain Cells for InvestigativePurposes II-20Device Implant in Brain Exhibits Therapeutic Potential for HD II-20Sangamo Biosciences on Path to Discover a Therapy for HD II-21Scientists at University of Rochester Medical CenterDemonstrate Use of Coenzyme Q10 for Reduction of OxidativeDamage in HD Patients II-21 McMaster University Discovers New Drug Candidate for Huntington's Disease II-22 University of Central Florida Researchers Test Role of DRP1Protein in HD II-22CMMT and Brain Research Centre Decode Cellular MechanismRelated to Alteration of Brain Cell Function in HD II-23

5. AN OVERVIEW OF HUNTINGTON'S DISEASE II-24Introduction II-24Historical Background II-24Prognosis II-25Stages of HD II-25Symptoms and Signs II-26Physical Symptoms II-26Emotional Symptoms II-27Mental Symptoms II-27Genetics of Huntington's Disease II-27Inheritance II-28Mechanism II-28Functions of HTT II-29Effects of mHTT on Cells II-29Macroscopic Effects of mHTT II-29Diagnosis of HD II-30Clinical Diagnosis II-30Embryonic Diagnosis II-30Differential Diagnosis II-31Diagnostic Tests for Huntington's Disease II-31Confirmatory Diagnostic Test II-31Pre-symptomatic Diagnostic Test II-31Prenatal Diagnostic Test II-31Treatment Options II-31Nutrition and Eating II-31Social Activity II-32Speech Therapy II-32Physical Therapy II-32Occupational Therapy II-33Medication II-33

6. CLINICAL TRIALS II-34Dimebon Fails Horizon Trials for Treatment of CognitiveDysfunction in HD Patients II-34Huntexil's Trials Prove only Borderline Benefits II-34AFQ056 in Phase II Clinical Study for Treatment of Chorea II-34Siena Biotech S.p.A. Undertakes Preparatory Steps for Phase IIstudy of SEN0014196 II-35Elontril in the Set-up Stage for Phase II Study II-35Alnylam Presents Positive Pre-clinical Data for its siRNA forsilencing the Mutant HTT II-357. RECENT INDUSTRY ACTIVITY II-36Roche Enters into Alliance with Isis Pharmaceuticals II-36Isis and CHDI Collaborate with KineMed II-36Omeros Receives IND Approval for OMS824 for Huntington's Disease II-37Teva Pharmaceutical Industries Signs Asset Transfer Agreementwith NeuroSearch II-38uniQure and Benitec Biopharma Ink Cross- Licensing Agreement II-38Evotec and CHDI Foundation Extend Collaboration II-38Raptor Acquires Exclusive Rights to Cysteamine and AssociatedCompounds II-38GNS Healthcare Enters into Collaboration with CHDI Foundation II-39Lundbeck Collaborates with CHDI Foundation for HD Research II-39Horizon Discovery Collaborates with Institute of Neurology,London II-40Thomson Reuters and CHDI Foundation Enter into MetaMinerPartnership II-40Targeted Genetics Changes Name to AmpliPhi Biosciences II-40Intellect Neurosciences Commences Initial Development ofCONJUMAB-A Platform Technology II-41CHDI Foundation and Galenea Collaborate II-41CHDI Foundation and Isis Pharmaceuticals Renew Collaboration II-41Sage Bionetworks and Takeda Pharmaceutical Enter into ResearchAlliance II-42Sage Bionetworks Extends Partnership with CHDI Foundation II-42 University of Dundee and GlaxoSmithKline to Collaborate overHD Research II-43

8. CORPORATE ACTIVITY IN THE RECENT PAST - A PERSPECTIVE BUILDER II-44Gladstone Institute and Taube-Koret to Collaborate withInstitute for Systems Biology II-44Alliance Pharma Concludes Distribution Deal with Biovail II-44Lundbeck Acquires LifeHealth II-44Lundbeck Acquires Ovation II-44Biovail Purchases Global Rights for Tetrabenazine from Cambridge II-45Raptor Pharmaceuticals, TorreyPines Conclude Merger II-45Cambridge Laboratories Enters into New Agreements forMarketing Xenazine® in North America II-45CHDI Foundation Inks Agreement with AMRI for Drug Discovery II-45Phytopharm Inks Agreement with CHDI Foundation to Evaluate Cogane II-46NeuroSearch Repurchases Global Rights to ACR16 II-46Raptor Pharmaceuticals Enters into Collaboration with CentreHospitalier Universitaire d'Angers for Phase II ClinicalTrial II-46Targeted Genetics Acquires Full Rights from Sirna Therapeuticsto siRNA Development Program II-47Cambridge Laboratories Receives Marketing Approval forTetrabenazine from Agencia Espanola de Medicamentos yProductos Sanitarios II-47Cambridge Laboratories Inks and Renews Agreements with Taiwan, New Zealand, Finland and Australia II-48CHDI Inked Collaboration Agreements with Galapagos II-48Biovail Acquires Prestwick Pharmaceuticals II-48Ovation Pharmaceuticals Acquires License to CommercializeXenazine® in the US II-49Aegera Therapeutics Inks License Agreement with Neurologix II-49

9. FOCUS ON SELECT PLAYERS II-50Alnylam Pharmaceuticals, Inc. (US) II-50AmpliPhi Biosciences Corp (US) II-50Ceregene, Inc. (US) II-50Cortex Pharmaceuticals, Inc. (US) II-51Intellect Neurosciences Incorporation (US) II-51Prana Biotechnology Limited ( Australia) II-52Raptor Pharmaceuticals Corp. (US) II-52Teva Pharmaceutical Industries Ltd ( Israel) II-53Trophos SA ( France) II-53Valeant Pharmaceuticals International, Inc. ( Canada) II-54Vertex Pharmaceuticals Incorporated (US) II-54

10. GLOBAL MARKET PERSPECTIVE II-55Table 1: Global Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Geographic Region - US, Europe and Rest of World Markets Independently Analyzed withAnnual Sales Figures in US$ Million for Years 2009 through2018 (includes corresponding Graph/Chart) II-55

Table 2: World 10-Year Perspective for Huntington's DiseaseTherapeutics by Geographic Region - Percentage Breakdown ofDollar Sales for US, Europe, and Rest of World Markets forYears 2009, 2013 & 2018 (includes corresponding Graph/Chart) II-56

III. MARKET1. THE UNITED STATES III-1A.Market Analysis III-1Outlook III-1HDSA Pushes for Improvement in Medicare Funding for Huntington's Disease III-1GINA for Reducing Discrimination Faced by People with HD III-2Strategic Corporate Developments III-2Select Players III-7B.Market Analytics III-10Table 3: The US Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics Analyzed with Annual SalesFigures in US$ Million for Years 2009 through 2018 (includescorresponding Graph/Chart) III-10

2. EUROPE III-11A.Market Analysis III-11Outlook III-11B.Market Analytics III-11Table 4: European Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Geographic Region - France, Germany, UK, Spain and Rest of Europe MarketsIndependently Analyzed with Annual Sales Figures in US$Million for Years 2009 through 2018 (includes correspondingGraph/Chart) III-11Table 5: European 10-Year Perspective for Huntington'sDisease Therapeutics by Geographic Region - PercentageBreakdown of Dollar Revenues for France, Germany, UK, Spainand Rest of Europe Markets for Years 2009, 2013 & 2018(includes corresponding Graph/Chart) III-12

2a. FRANCE III-13A.Market Analysis III-13Outlook III-13Trophos SA - A Key Player III-13B.Market Analytics III-14Table 6: French Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics Analyzed with Annual SalesFigures in US$ Million for Years 2009 through 2018 (includescorresponding Graph/Chart) III-142b. GERMANY III-15A.Market Analysis III-15Outlook III-15Strategic Corporate Development III-15B.Market Analytics III-16Table 7: German Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics Analyzed with Annual SalesFigures in US$ Million for Years 2009 through 2018 (includescorresponding Graph/Chart) III-16

2c. THE UNITED KINGDOM III-17A.Market Analysis III-17Outlook III-17Table 8: Juvenile HD Incidence Estimates in the UK(includes corresponding Graph/Chart) III-17Table 9: Juvenile HD Prevalence Estimates in the UK(2006-2010) (includes corresponding Graph/Chart) III-17Strategic Corporate Developments III-18B.Market Analytics III-19Table 10: The UK Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics Analyzed with Annual SalesFigures in US$ Million for Years 2009 through 2018 (includescorresponding Graph/Chart) III-19

2d. SPAIN III-20A.Market Analysis III-20Outlook III-20B.Market Analytics III-20Table 11: Spanish Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics Analyzed with Annual SalesFigures in US$ Million for Years 2009 through 2018 (includescorresponding Graph/Chart) III-202e. REST OF EUROPE III-21A.Market Analysis III-21Outlook III-21Strategic Corporate Development III-21B.Market Analytics III-22Table 12: Rest of Europe Recent Past, Current & FutureAnalysis for Huntington's Disease Therapeutics Analyzed withAnnual Sales Figures in US$ Million for Years 2009 through2018 (includes corresponding Graph/Chart) III-22

3. REST OF WORLD III-23A.Market Analysis III-23Outlook III-23Strategic corporate development III-23Select players III-23B.Market Analytics III-25Table 13: Rest of World Recent Past, Current & FutureAnalysis for Huntington's Disease Therapeutics Analyzed withAnnual Sales Figures in US$ Million for Years 2009 through2018 (includes corresponding Graph/Chart) III-25

IV. COMPETITIVE LANDSCAPETotal Companies Profiled: 35 (including Divisions/Subsidiaries - 36) The United States (18) Canada (2) Europe (13)- France (1)- Germany (1)- The United Kingdom (3)- Italy (1)- Rest of Europe (7) Asia-Pacific (Excluding Japan) (2) Middle East (1)

To order this report: Therapy Industry: Global Huntington%s Disease Therapeutics Industry

Contact Clare:  US:(339) 368 6001 Intl:+1 339 368 6001

SOURCE Reportlinker

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
GOOG $683.11 0.00%
FB $101.91 0.00%
TSLA $150.47 0.00%
YHOO $26.76 0.00%
AAPL $93.70 0.00%


Chart of I:DJI
DOW 15,660.18 -254.56 -1.60%
S&P 500 1,829.08 -22.78 -1.23%
NASDAQ 4,266.8370 -16.7550 -0.39%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs